EP0403333A3
Nucleotide sequences of retroviral genomes of types hiv-i, hiv-2 and siv, their uses for the amplification of these genomes and diagnosis in vitro of these viral infections
Abstract
The present invention relates to nucleotide sequences derived from genomes of viruses of the HIV-1 type, or genomes of viruses of the HIV-2 type, or of the SIV-type viruses, and their applications, in particular as oligonucleotide primers for the implementation of the invention. implementation of diagnostic method in vitro infection of an individual with an HIV-1 and / or HIV-2 virus.
Term
Term ended
Projected expiry passed 5 June 2010, 16.3 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
Every citation, both waysCites: the store holds 7 of 8
| Document | Relation | Office | Category | Cited during |
|---|---|---|---|---|
| EP0229701A2 | Cites | European Patent Office (EPO) | X | Search report |
| EP0269445A2 | Cites | European Patent Office (EPO) | X | Search report |
| EP0269520A2 | Cites | European Patent Office (EPO) | Y | Search report |
| EP0272098A2 | Cites | European Patent Office (EPO) | X | Search report |
| WO8707300A2 | Cites | World Intellectual Property Organization (WIPO) | Y | Search report |
| WO8707906A1 | Cites | World Intellectual Property Organization (WIPO) | Y | Search report |
| WO8805440A1 | Cites | World Intellectual Property Organization (WIPO) | Y | Search report |
| THE LANCET, vol. 2, 16 septembre 1989, pages 637-639, The Lancet Ltd; C.R. HORSBURGH, Jr.: "Duration of human immunodeficiency virus infection before detection of antibody", page 638, colonne de gauche, dernier alinea. | Non-patent | – | – | Search report |
| SCIENCE, vol. 239, 15 janvier 1988, pages 295-297; C.-H. OU et al.: "DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells", le tableau 2. | Non-patent | – | – | Search report |
| THE JOURNAL OF INFECTIOUS DISEASES, vol. 158, no. 6, décembre 1988, pages 1170-1176; M. RAYFIELD et al.: "Mixed human immunodeficiency virus (HIV) infection in a individual: Demonstration of both HIV type 1 and type 2 proviral sequences by using polymerase chain reaction", le tableau 1. | Non-patent | – | – | Search report |
| PROC. NATL. ACAD. SCI. USA, vol. 86, avril 1989, pages 2423-2427; D.J. KEMP et al.: "Colorimetric detection of specific DNA segments amplified by polymerase chain reactions", page 2424, lignes 1-23. | Non-patent | – | – | Search report |
| CELL, vol. 58, no. 5, 8 septembre 1989, pages 901-910, Cell Press; A. MEYERHANS et al.: "Temporal fluctuations in HIV Quasispecies in vivo are not reflected by sequential HIV isolations", colonne de gauche, dernier alinea. | Non-patent | – | – | Search report |
72 members in 13 offices
Priority claims8
| Document | Office | Kind | Date |
|---|---|---|---|
| 8907354 | France | A | |
| 8907354 | France | A | |
| 8907354 | France | – | |
| 8912371 | France | A | |
| 8912371 | France | A | |
| 8912371 | France | – | |
| FR19890007354 | – | – | – |
| FR19890012371 | – | – | – |
Members72
| Document | Office | Kind | |
|---|---|---|---|
| CA2062829A1 | Canada | A1 | |
| FR2647809A1 | France | A1 | |
| CA2585164A1 | Canada | A1 | |
| CA2685262A1 | Canada | A1 | |
| WO9015066A2 | World Intellectual Property Organization (WIPO) | A2 | |
| EP0403333A2 | European Patent Office (EPO) | A2 | |
| FR2652091A1 | France | A1 | |
| WO9015066A3 | World Intellectual Property Organization (WIPO) | A3 | |
| FR2647809B1 | France | B1 | |
| EP0403333A3This record | European Patent Office (EPO) | A3 | |
| JPH04507043A | Japan | A | |
| FR2652091B1 | France | B1 | |
| EP0806484A2 | European Patent Office (EPO) | A2 | |
| US5688637A | United States of America | A | |
| SG47868A1 | Singapore | A1 | |
| US5786177A | United States of America | A | |
| EP0403333B1 | European Patent Office (EPO) | B1 | |
| AT185379T | Austria | T | |
| ATE185379T1 | Austria | T1 | |
| DE69033311D1 | Germany | D1 | |
| ES2139567T3 | Spain | T3 | |
| DE69033311T2 | Germany | T2 | |
| DK0403333T3 | Denmark | T3 | |
| JP2000093187A | Japan | A | |
| GR3032261T3 | Greece | T3 | |
| EP0806484A3 | European Patent Office (EPO) | A3 | |
| US6194142B1 | United States of America | B1 | |
| JP3428012B2 | Japan | B2 | |
| US2005037340A1 | United States of America | A1 | |
| US2006035260A1 | United States of America | A1 | |
| US7022814B1 | United States of America | B1 | |
| EP1642987A2 | European Patent Office (EPO) | A2 | |
| EP0806484B1 | European Patent Office (EPO) | B1 | |
| AT323183T | Austria | T | |
| ATE323183T1 | Austria | T1 | |
| DE69034220D1 | Germany | D1 | |
| US7078516B1 | United States of America | B1 | |
| DK0806484T3 | Denmark | T3 | |
| EP1642987A3 | European Patent Office (EPO) | A3 | |
| EP1715064A1 | European Patent Office (EPO) | A1 | |
| ES2262166T3 | Spain | T3 | |
| DE69034220T2 | Germany | T2 | |
| HK1092839A1 | Hong Kong, China | A1 | |
| DE05014676T1 | Germany | T1 | |
| EP1715064A8 | European Patent Office (EPO) | A8 | |
| ES2275451T1 | Spain | T1 | |
| HK1097574A1 | Hong Kong, China | A1 | |
| CA2062829C | Canada | C | |
| EP1642987B1 | European Patent Office (EPO) | B1 | |
| AT404699T | Austria | T | |
| ATE404699T1 | Austria | T1 | |
| DE69034260D1 | Germany | D1 | |
| DK1642987T3 | Denmark | T3 | |
| EP2011888A1 | European Patent Office (EPO) | A1 | |
| ES2275451T3 | Spain | T3 | |
| EP1715064B1 | European Patent Office (EPO) | B1 | |
| AT423856T | Austria | T | |
| ATE423856T1 | Austria | T1 | |
| ES2315215T1 | Spain | T1 | |
| DE69034265D1 | Germany | D1 | |
| DE07025195T1 | Germany | T1 | |
| ES2321326T3 | Spain | T3 | |
| DK1715064T3 | Denmark | T3 | |
| HK1125136A1 | Hong Kong, China | A1 | |
| CA2585164C | Canada | C | |
| EP2011888B1 | European Patent Office (EPO) | B1 | |
| AT466111T | Austria | T | |
| ATE466111T1 | Austria | T1 | |
| DE69034267D1 | Germany | D1 | |
| US7759477B2 | United States of America | B2 | |
| DK2011888T3 | Denmark | T3 | |
| US7777020B2 | United States of America | B2 |
55 legal events, as 7 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Se: european patent has lapsedLapsedEUG | EUG | EP | |
| Be: patent expiredExpiredBE20 | BE20 | EP | |
| Be: patent expiredExpiredBE20 | BE20 | EP | |
| Patent expired after termination of 20 yearsExpiredPE20 | PE20 | GB | |
| Ep patent expiredExpiredEUP | EUP | DK | |
| Patent ceasedCeasedPL | PL | CH | |
| Discontinued because of reaching the maximum lifetime of a patentV4 | V4 | NL | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| European patent in force as of 2002-01-01IF02 | IF02 | GB | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Change of name or company nameCD | CD | FR | |
| Concession to grant licencesCL | CL | FR | |
| Ep patent with danish claimsT3 | T3 | DK | |
| Definitive protectionFG2A | FG2A | ES | |
| Gb: translation of ep patent filed (gb section 77(6)(a)/1977)GBT | GBT | EP | |
| New agentNV | NV | CH | |
| It: translation for a ep patent filedITF | ITF | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| Corresponds to:REF | REF | EP | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| Designated contracting statesAK | AK | EP | |
| Corresponds to:REF | REF | EP | |
| Miscellaneous (additional remarks)TEILANMELDUNG 97110543.2 EINGEREICHT AM 27/06/97.XX | XX | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOS IGRAGRAH | GRAH | EP | |
| Despatch of communication of intention to grantORIGINAL CODE: EPIDOS AGRAGRAG | GRAG | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOS IGRAGRAH | GRAH | EP | |
| Despatch of communication of intention to grantORIGINAL CODE: EPIDOS AGRAGRAG | GRAG | EP | |
| Despatch of communication of intention to grantORIGINAL CODE: EPIDOS AGRAGRAG | GRAG | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed17P | 17P | EP | |
| New documents despatched to applicant after publication of the search report16A | 16A | EP | |
| Designated contracting statesAK | AK | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 0403333
- Publication, DOCDB
- 0403333
- Publication, EPODOC
- EP0403333
- Application
- 401520
- Application, DOCDB
- 90401520
- Application, EPODOC
- EP19900401520
Titles3
- German
- Nukleotid-Sequenzen des Genoms von Retroviren vom Typ HIV-1, HIV-2 und SIV, ihre Verwendungen zur Amplifikation dieser Genome und in-vitro-Diagnose dieser viralen Infektionen
- English
- Nucleotide sequences of retroviral genomes of types HIV-I, HIV-2 and SIV, their uses for the amplification of these genomes and diagnosis in vitro of these viral infections
- French
- Séquences nucléotidiques issues du génome des rétrovirus du typ hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des génomes de ces rétrovirus et pour le diagnostic in-vitro des infections dues à ces virus
Classification
- CPC, 10
- C07K14/005
- A61K38/00
- A61K39/00
- C12N2740/15022
- C12N2740/16022
- C12Q1/703
- G01N2333/16
- Y10S435/974
- Y10S435/975
- A61P31/18
- IPC, 15
- A61K39 00
- A61K39 21
- A61K48 00
- A61P31 18
- C07H21 04
- C07K14 00
- C07K14 155
- C07K14 16
- C07K16 00
- C07K16 10
- C12N15 09
- C12N15 49
- C12Q1 68
- C12Q1 70
- G01N33 569
Designated states1
- Contracting states, 1
- Sweden